Seeking Alpha

Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after...

Cancer-focused biotech GTx (GTXI +7.1%) moves higher on double its 10-day average volume after Stifel Nicolaus initiates coverage with a Buy rating citing "a potentially significant value-creating event … with the pending Enobosarm Phase 3 data." Price target is $7, representing a 40% upside from the stock's current price. 
Comments (1)
  • karlis44
    , contributor
    Comments (64) | Send Message
     
    Embosarm is an important advance in medicine. SARM's are novel to
    the anabolic market. Likely will advance quickly.
    I am behind it.
    Karlis Ullis, MD
    kullismd@gmail.com
    http://bit.ly/ZeKX1x
    6 Apr 2013, 02:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs